Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
28 7월 2023 - 12:20PM
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of pathologic mineralization and intimal proliferation,
today announced the pricing of an underwritten public offering of
12,500,000 shares of its common stock at a price of $4.80 per
share, for aggregate gross proceeds of approximately $60 million,
before deducting underwriting discounts and commissions and other
offering expenses. In addition, Inozyme has granted the
underwriters an option for a period of 30 days to purchase up to an
additional 1,875,000 shares of common stock at the public offering
price, less the underwriting discounts and commissions. All of the
shares of common stock are being offered by Inozyme.
BofA Securities, TD Cowen and Piper Sandler are
acting as joint book-running managers for the offering. Wedbush
PacGrow and Needham & Company are acting as co-managers for the
offering. The offering is expected to close on or about August 1,
2023, subject to satisfaction of customary closing conditions.
A shelf registration statement on Form S-3 (File
No. 333-258702) relating to the shares of common stock offered in
the public offering was filed with the Securities and Exchange
Commission (the “SEC”) on August 11, 2021 and became effective on
August 23, 2021. The offering was made only by means of a
prospectus supplement and accompanying prospectus that form a part
of the registration statement. A preliminary prospectus supplement
relating to and describing the terms of the offering has been filed
with the SEC and may be obtained for free by visiting the SEC’s
website at www.sec.gov. A final prospectus supplement relating to
the offering will be filed with the SEC. Copies of the preliminary
prospectus supplement and final prospectus supplement, when
available, and the accompanying prospectus relating to the offering
may also be obtained by contacting: BofA Securities, NC1-022-02-25,
201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus
Department, or by email at: dg.prospectus_requests@bofa.com; TD
Cowen, 599 Lexington Avenue, New York, NY 10022, or by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Piper Sandler, Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, or by telephone at (800)
747-3924, or by email at prospectus@psc.com.
This press release does not constitute an offer
to sell, or a solicitation of an offer to buy these securities, nor
shall there be any sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc. is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue
and skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical trials for the
treatment of ENPP1 Deficiency and ABCC6 Deficiency.
Cautionary Note Regarding
Forward-Looking Statements
Statements in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements regarding the proposed public
offering, including the satisfaction of customary closing
conditions relating to the offering and the expected closing of the
public offering. The words “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Inozyme may not actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements, and you should not place undue reliance on its
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements Inozyme makes as a result of various
risks and uncertainties, including but not limited to satisfaction
of customary closing conditions related to the public offering,
whether Inozyme will be able to conduct, complete and receive
results from clinical trials for its product candidates on its
expected timelines, or at all, whether its cash resources will be
sufficient to fund its foreseeable and unforeseeable operating
expenses and capital expenditure requirements on its expected
timeline and other important factors discussed in the “Risk
Factors” sections contained in its annual report on file with the
SEC. The forward-looking statements included in this press release
represent Inozyme’s views as of the date hereof and should not be
relied upon as representing its views as of any date subsequent to
the date hereof. Inozyme anticipates that subsequent events and
developments will cause its views to change. However, while Inozyme
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do
so.
Contacts
Investors:Inozyme PharmaStefan Riley, Director of IR and
Corporate Communications(857)
330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt
Pera973-886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Inozyme Pharma (NASDAQ:INZY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024